Skip to main content

Eurofins in war of words with ‘activist short seller’

10th July 2024

Submitted by:

Andrew Warmington

Pennsylvania based ‘activist short seller’ Muddy Waters has announced it is short on diagnostics and lab testing group Eurofins Scientific because the confusion and contradictions inherent in its financials and operations cause us to believe that it is optimised for malfeasance, rather than for conventional business”. This has provoked a strong response.

Referring to CEO Dr Gilles Martin, who owns about one third of the company, Muddy Waters said: “At best, Eurofins has a parasitic controlling shareholder who has been siphoning money from the company for two decades. Our view, however, is that Eurofins’ financials could contain material overstatements of profits, cash balances and other asset values.”

Among other things, the short seller noted that the acquisitions Eurofins has made have become smaller even as it grows larger, with the average value of the acquired firm falling to $3.1 million in 2023. “The vast majority of the acquisitions don’t meet the threshold for disclosure, keeping much of the spending opaque,” it said.

Muddy Waters also noted that Eurofins’ auditor had to reclassify €682 million of receivables and payables in the 2022 accounts, despite its claims not to be overly complex, and that it was paying Martin much more than it should have been if it was not buying real estate. The implication is that Martin has siphoned money to fund his real estate empire.

In addition, the firm said, Eurofins pays its employees, other than managers of large business units well below industry rates and has raised billions of dollars in recent years, supposedly to fund growth. “In our view, there is an explanation that unifies these, and other, contradictions: Eurofins is optimised for malfeasance. We are unclear how deep the rot goes, but we suspect that it extends to reporting of revenue, profits, cash and other asset accounts.”

In response, Eurofins said that all of the allegations and insinuations are “either inaccurate, irrelevant, biased and/or misleading”. The company “is completely confident in the integrity of its accounts, operational performance, internal controls and risk management”, all real estate transactions have been done “at arm's length terms” and all cash amounts were properly audited at local and consolidated levels.

Eurofins added that Muddy Waters has never participated in its investor events or directly engaged, and indeed stands to gain from a fall in share price. (This happened immediately after the report was issued, though the price has since recovered.) Among the “most blatantly wrong and/or misleading allegations”, Eufofins highlighted:

* Making an unsuitable comparison between Eurofins’ purchase of BioSanté in Martinique to investments in travel and tourism *

Citing some specific local GAAP requirements in how to report cash and equivalents in condensed local statutory accounts filings to build a story about potential double-counting of cash at group level, when all these inter-company transactions are eliminated in the consolidated financials

* Using incorrect addresses and wrong values to paint a purchase from unrelated real estate developers as a deliberate act to facilitate a mark-up of the property via a straw buyer

* Alleging that spreadsheets are extensively used for reporting and with “unacceptably loose internal controls” when the company has actually utilised recognised technologies for many years

* Highlighting that the ratios of revenues and costs per employee are higher than some companies active in the TIC sector, and thus too good to be true, while there are obvious geographical, service and sectoral effects, and Eurofins’ activities are very different from TIC

The company reiterated its confidence in the integrity of its accounts, operational performance, internal controls and risk management. It provided detailed examples of this and vowed to publish more as needed. “It appears deeply slanderous to me, and undoubtably also to our employees, bondholders, shareholders and other stakeholders, to see these baseless accusations levelled against us. We will spare no effort to ensure the truth is made clear to all,” Martin said.

Another investor in Eurofins, David Herro of Chicago-based Harris Associates, also defended the firm, saying that Muddy Waters had “failed to offer a compelling argument”. It had offered no specific instances of wrongdoing and some of its claims were “extremely hollow” in view of Martin’s own stake in the firm, Herro said.

UPL to split out specialities

Indian agrochemicals giant UPL has announced plans to transfer its speciality chemicals business, including agrochemical

Submitted by:

Andrew Warmington

AI for SAPs

Together with Algo Artis, Japan’s Nippon Shokubai has developed an algorithm-based means for the production

Submitted by:

Andrew Warmington

Nippon Shokubai's API Facility in Japan

Nucleic acid API boost

Nippon Shokubai is to expand its GMP capacity for nucleic APIs tenfold It will install

Submitted by:

Andrew Warmington

Flamma's facility in Dalian

Flamma opens in China

Italian CDMO Flamma Group has officially opened its new cGMP plant at Dalian, China, where

Submitted by:

Andrew Warmington

GL Chemtec has opened a new kilo lab

GL Chemtec completes kilo lab

CDMO GL Chemtec has announced the completion of a cGMP kilo lab at Oakville, Ontario

Submitted by:

Andrew Warmington

Sterling's facility at Deeside, UK

CDMOs in ADC investments

Five CDMOs across the world have separately announced investments in antibody-drug conjugates (ADCs). Piramal Pharma is

Submitted by:

Andrew Warmington

Afyren Neoxy plant

Milestones for two greentech firms

Afyren has achieved continuous production at its Afyren Neoxy plant at Clermont-Ferrand (pictured)

Submitted by:

Andrew Warmington

Origin by Ocean derives its materials from sargassum

CABB in algae biorefinery deal

CABB has agreed a strategic partnership to establish a first-in-kind algae biorefinery at its site at Kokkola

Submitted by:

Andrew Warmington

First waste-based biosurfactants

Belgian start-up AmphiStar has launched what it claims are the first fully upcycled biobased surfactants

Submitted by:

Andrew Warmington

Aether to supply Seqens

Indian firm Aether Industries has entered into a manufacturing agreement with Chemoxy International, a UK-based

Submitted by:

Andrew Warmington

New model for biocatalysts

BASF, the Austrian Research Centre of Industrial Biotechnology (ACIB) and the University of Graz in

Submitted by:

Andrew Warmington

CBE JU funds 31 more projects

The Circular Bio-based Europe Joint Undertaking (CBE JU), a €2 billion partnership between the EU

Submitted by:

Andrew Warmington

Ribbon cutting ceremony at Lubrizol's new office

Lubrizol opens London office

Lubrizol has opened a new office in Hammersmith, London. This will be home to a

Submitted by:

Andrew Warmington

Sudarshan to buy Heubach

India’s Sudarshan Chemical Industries (SCIL) has entered into a definitive agreement to acquire the Heubach

Submitted by:

Andrew Warmington

Alliance in natural fragrances

Sensegen, a US-based specialist in biotech-enabled fragrances, notably a new class of natural musk raw

Submitted by:

Andrew Warmington

Croda breaks ground in China

Croda International has broken ground for a low-carbon, multi-purpose production facility on a greenfield site

Submitted by:

Andrew Warmington

CCT collaboration for Givaudan

Flavours and fragrances giant Givaudan has agreed a research collaboration for the development of sustainable

Submitted by:

Andrew Warmington

REACH Authorisation

Candidate List ‘reaches’ 250

The European Chemicals Agency (ECHA) has added three more substances to the Candidate List of

Submitted by:

Andrew Warmington

Staff at Brenntag's newly acquired Czech site

CO2-free distribution site first

Brenntag has officially inaugurated what it claims to be the first CO2-emission-free chemical distribution site

Submitted by:

Andrew Warmington